BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)
Published: 18 Mar-2015
DOI: 10.3833/pdr.v2015.i3.2098 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In by far the largest deal to date in the immuno-oncology sector in terms of upfront consideration, Bristol-Myers Squibb (BMS) has agreed to acquire start-up Flexus Biosciences for US$800 M plus up to US$450 M in development milestones that could be achieved within 3 years...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS